Exchange: NYSEArca·Updated 07:34 PM EDT

VHT News

News
all
press releases
MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.
Stocktwits
More News
Which Healthcare ETF Is the Better Buy: Vanguard's VHT or iShares' IXJ?
Key PointsThe Vanguard Health Care ETF (VHT) is significantly cheaper to own than the iShares Global Healthcare ETF (IXJ...
Nasdaq News: Markets
Should You Invest in the Vanguard Health Care Index Fund ETF Shares (VHT)?
Sector ETF report for VHT
Zacks
Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026?
Key PointsVanguard Health Care ETF offers much broader diversification with 411 holdings compared to the 60 stocks in State Street Health Care Select Sector SPDR ETF...
Nasdaq News: Markets
DOCS Stock Soars After CEO Says Clinical AI Outperformed Anthropic, Wall Street Lifts Price Targets
CEO Jeff Tangney said Doximity's AI recorded a 4.8% error rate versus 13.6% for Anthropic's Fable 5.
Stocktwits
MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
MoonLake has consistently guided for a “mid-2026” primary endpoint readout from IZAR-1, its late-stage trial for sonelokimab in certain patients with active psoriatic arthritis.
Stocktwits
VHT vs. PBE: Which Health Care ETF Is the Better Buy?
Key PointsThe Vanguard Health Care ETF (VHT) offers broader health care exposure and has a a lower expense ratio than the Invesco Biotechnology & Genome ETF (PBE...
Nasdaq News: Markets
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees
Key PointsVanguard Health Care ETF offers a lower expense ratio and a higher dividend yield than VanEck Biotech ETF...
Nasdaq News: Markets
UnitedHealth Pulls Back Post 52-Week High: Healthcare ETFs to Watch
UNH's post-earnings pullback follows a 52-week high, as stronger guidance offsets Medicaid pressures and spotlights healthcare ETFs with sizable exposure.
Zacks
ETFs to Buy Post JNJ's Q2 Earnings Beat & Bullish 2026 Outlook
Johnson & Johnson's Q2 beat and strong pharma momentum are raising interest in healthcare ETFs with sizable exposure to the company.
Zacks

Advertisement|Remove ads.